Novartis invests in Selexys with exclusive option to acquire the company; option exercised
- Large Molecule
- Includes M&A Option
- Includes Equity
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.